128 results
Page 3 of 7
8-K
EX-99.1
suk63c0fuqlorvjibfhw
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
fj4kic5d6bflgb5i75
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
bk5qs
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
t89jglx1
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
8-K
EX-99.1
4wne3lye3j64xk7
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
qu2lm
20 Nov 20
Regulation FD Disclosure
7:36am
S-3ASR
vkd9d6pkldwdxboih2
10 Aug 20
Automatic shelf registration
5:01pm
424B5
5dc9ms 99
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
orp2dfnft vm30q5739
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
ew5g1v hl
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
ji9ezpa2io1yxgh
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am